nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Chlorambucil—ovarian cancer	0.351	1	CrCtD
Melphalan—Alkylating Activity—Altretamine—ovarian cancer	0.252	0.635	CiPCiCtD
Melphalan—breast cancer—ovarian cancer	0.205	1	CtDrD
Melphalan—Alkylating Activity—Chlorambucil—ovarian cancer	0.145	0.365	CiPCiCtD
Melphalan—SLC7A5—myometrium—ovarian cancer	0.000821	0.0808	CbGeAlD
Melphalan—SLC7A5—epithelium—ovarian cancer	0.000644	0.0634	CbGeAlD
Melphalan—SLC7A5—uterine cervix—ovarian cancer	0.000639	0.0629	CbGeAlD
Melphalan—SLC7A5—decidua—ovarian cancer	0.000609	0.0599	CbGeAlD
Melphalan—SLC7A5—endometrium—ovarian cancer	0.000578	0.0569	CbGeAlD
Melphalan—SLC7A5—gonad—ovarian cancer	0.000536	0.0527	CbGeAlD
Melphalan—SLC7A5—uterus—ovarian cancer	0.000532	0.0524	CbGeAlD
Melphalan—SLC22A3—myometrium—ovarian cancer	0.00051	0.0501	CbGeAlD
Melphalan—SLC22A3—embryo—ovarian cancer	0.00049	0.0482	CbGeAlD
Melphalan—SLC7A5—female reproductive system—ovarian cancer	0.000479	0.0471	CbGeAlD
Melphalan—SLC7A5—bone marrow—ovarian cancer	0.000452	0.0445	CbGeAlD
Melphalan—SLC7A5—female gonad—ovarian cancer	0.000436	0.0429	CbGeAlD
Melphalan—SLC7A5—vagina—ovarian cancer	0.000433	0.0426	CbGeAlD
Melphalan—SLC22A3—uterine cervix—ovarian cancer	0.000397	0.039	CbGeAlD
Melphalan—SLC7A5—testis—ovarian cancer	0.000386	0.038	CbGeAlD
Melphalan—SLC22A3—endometrium—ovarian cancer	0.000359	0.0353	CbGeAlD
Melphalan—SLC22A3—gonad—ovarian cancer	0.000333	0.0327	CbGeAlD
Melphalan—SLC22A3—female reproductive system—ovarian cancer	0.000297	0.0292	CbGeAlD
Melphalan—SLC7A5—lymph node—ovarian cancer	0.00028	0.0276	CbGeAlD
Melphalan—SLC22A3—female gonad—ovarian cancer	0.00027	0.0266	CbGeAlD
Melphalan—SLC22A3—vagina—ovarian cancer	0.000269	0.0264	CbGeAlD
Melphalan—SLC22A3—testis—ovarian cancer	0.00024	0.0236	CbGeAlD
Melphalan—SLC22A3—lymph node—ovarian cancer	0.000174	0.0171	CbGeAlD
Melphalan—Ibuprofen—CXCL8—ovarian cancer	0.000108	0.801	CrCbGaD
Melphalan—SLC22A3—Abacavir transmembrane transport—ABCB1—ovarian cancer	9.07e-05	0.157	CbGpPWpGaD
Melphalan—SLC22A3—Abacavir transport and metabolism—ABCB1—ovarian cancer	5.21e-05	0.0901	CbGpPWpGaD
Melphalan—Fatigue—Topotecan—ovarian cancer	4.84e-05	0.00134	CcSEcCtD
Melphalan—Anaphylactic shock—Vinorelbine—ovarian cancer	4.8e-05	0.00133	CcSEcCtD
Melphalan—Pain—Topotecan—ovarian cancer	4.8e-05	0.00133	CcSEcCtD
Melphalan—Hepatobiliary disease—Paclitaxel—ovarian cancer	4.79e-05	0.00132	CcSEcCtD
Melphalan—Hepatocellular injury—Doxorubicin—ovarian cancer	4.79e-05	0.00132	CcSEcCtD
Melphalan—Infection—Vinorelbine—ovarian cancer	4.77e-05	0.00132	CcSEcCtD
Melphalan—Injection site reaction—Doxorubicin—ovarian cancer	4.76e-05	0.00131	CcSEcCtD
Melphalan—Bronchospasm—Docetaxel—ovarian cancer	4.73e-05	0.00131	CcSEcCtD
Melphalan—Thrombocytopenia—Vinorelbine—ovarian cancer	4.7e-05	0.0013	CcSEcCtD
Melphalan—Tachycardia—Vinorelbine—ovarian cancer	4.68e-05	0.00129	CcSEcCtD
Melphalan—Bladder pain—Epirubicin—ovarian cancer	4.68e-05	0.00129	CcSEcCtD
Melphalan—Neoplasm—Epirubicin—ovarian cancer	4.68e-05	0.00129	CcSEcCtD
Melphalan—Mouth ulceration—Epirubicin—ovarian cancer	4.68e-05	0.00129	CcSEcCtD
Melphalan—Cystitis noninfective—Doxorubicin—ovarian cancer	4.67e-05	0.00129	CcSEcCtD
Melphalan—Skin disorder—Vinorelbine—ovarian cancer	4.66e-05	0.00129	CcSEcCtD
Melphalan—Hypersensitivity—Chlorambucil—ovarian cancer	4.64e-05	0.00128	CcSEcCtD
Melphalan—Cystitis—Doxorubicin—ovarian cancer	4.62e-05	0.00128	CcSEcCtD
Melphalan—Anorexia—Vinorelbine—ovarian cancer	4.57e-05	0.00126	CcSEcCtD
Melphalan—Skin exfoliation—Doxorubicin—ovarian cancer	4.57e-05	0.00126	CcSEcCtD
Melphalan—Pancytopenia—Docetaxel—ovarian cancer	4.57e-05	0.00126	CcSEcCtD
Melphalan—Haemoglobin—Paclitaxel—ovarian cancer	4.57e-05	0.00126	CcSEcCtD
Melphalan—Haemorrhage—Paclitaxel—ovarian cancer	4.54e-05	0.00126	CcSEcCtD
Melphalan—Asthenia—Chlorambucil—ovarian cancer	4.52e-05	0.00125	CcSEcCtD
Melphalan—Neutropenia—Docetaxel—ovarian cancer	4.5e-05	0.00124	CcSEcCtD
Melphalan—Neuropathy—Doxorubicin—ovarian cancer	4.49e-05	0.00124	CcSEcCtD
Melphalan—Urinary tract disorder—Paclitaxel—ovarian cancer	4.49e-05	0.00124	CcSEcCtD
Melphalan—Hypotension—Vinorelbine—ovarian cancer	4.48e-05	0.00124	CcSEcCtD
Melphalan—Connective tissue disorder—Paclitaxel—ovarian cancer	4.46e-05	0.00123	CcSEcCtD
Melphalan—Pruritus—Chlorambucil—ovarian cancer	4.46e-05	0.00123	CcSEcCtD
Melphalan—Urticaria—Topotecan—ovarian cancer	4.46e-05	0.00123	CcSEcCtD
Melphalan—Urethral disorder—Paclitaxel—ovarian cancer	4.45e-05	0.00123	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	4.37e-05	0.00121	CcSEcCtD
Melphalan—Neoplasm—Doxorubicin—ovarian cancer	4.33e-05	0.0012	CcSEcCtD
Melphalan—Mouth ulceration—Doxorubicin—ovarian cancer	4.33e-05	0.0012	CcSEcCtD
Melphalan—Bladder pain—Doxorubicin—ovarian cancer	4.33e-05	0.0012	CcSEcCtD
Melphalan—Diarrhoea—Chlorambucil—ovarian cancer	4.31e-05	0.00119	CcSEcCtD
Melphalan—Paraesthesia—Vinorelbine—ovarian cancer	4.31e-05	0.00119	CcSEcCtD
Melphalan—Dyspnoea—Vinorelbine—ovarian cancer	4.28e-05	0.00118	CcSEcCtD
Melphalan—Flushing—Paclitaxel—ovarian cancer	4.22e-05	0.00116	CcSEcCtD
Melphalan—Neuropathy peripheral—Docetaxel—ovarian cancer	4.2e-05	0.00116	CcSEcCtD
Melphalan—Jaundice—Docetaxel—ovarian cancer	4.18e-05	0.00116	CcSEcCtD
Melphalan—Stomatitis—Docetaxel—ovarian cancer	4.18e-05	0.00116	CcSEcCtD
Melphalan—Decreased appetite—Vinorelbine—ovarian cancer	4.17e-05	0.00115	CcSEcCtD
Melphalan—Gastrointestinal disorder—Vinorelbine—ovarian cancer	4.14e-05	0.00114	CcSEcCtD
Melphalan—Fatigue—Vinorelbine—ovarian cancer	4.14e-05	0.00114	CcSEcCtD
Melphalan—Hypersensitivity—Topotecan—ovarian cancer	4.13e-05	0.00114	CcSEcCtD
Melphalan—Pain—Vinorelbine—ovarian cancer	4.1e-05	0.00113	CcSEcCtD
Melphalan—Immune system disorder—Paclitaxel—ovarian cancer	4.1e-05	0.00113	CcSEcCtD
Melphalan—Mediastinal disorder—Paclitaxel—ovarian cancer	4.09e-05	0.00113	CcSEcCtD
Melphalan—Renal failure acute—Epirubicin—ovarian cancer	4.07e-05	0.00112	CcSEcCtD
Melphalan—Arrhythmia—Paclitaxel—ovarian cancer	4.06e-05	0.00112	CcSEcCtD
Melphalan—Hepatobiliary disease—Docetaxel—ovarian cancer	4.06e-05	0.00112	CcSEcCtD
Melphalan—SLC22A3—Synaptic Vesicle Pathway—NSF—ovarian cancer	4.06e-05	0.0702	CbGpPWpGaD
Melphalan—Asthenia—Topotecan—ovarian cancer	4.02e-05	0.00111	CcSEcCtD
Melphalan—Alopecia—Paclitaxel—ovarian cancer	4.01e-05	0.00111	CcSEcCtD
Melphalan—Vomiting—Chlorambucil—ovarian cancer	4.01e-05	0.00111	CcSEcCtD
Melphalan—Pruritus—Topotecan—ovarian cancer	3.97e-05	0.0011	CcSEcCtD
Melphalan—SLC7A5—Basigin interactions—CAV1—ovarian cancer	3.89e-05	0.0672	CbGpPWpGaD
Melphalan—Haemoglobin—Docetaxel—ovarian cancer	3.87e-05	0.00107	CcSEcCtD
Melphalan—Hepatitis—Docetaxel—ovarian cancer	3.85e-05	0.00106	CcSEcCtD
Melphalan—Haemorrhage—Docetaxel—ovarian cancer	3.85e-05	0.00106	CcSEcCtD
Melphalan—Diarrhoea—Topotecan—ovarian cancer	3.84e-05	0.00106	CcSEcCtD
Melphalan—Urticaria—Vinorelbine—ovarian cancer	3.81e-05	0.00105	CcSEcCtD
Melphalan—Urinary tract disorder—Docetaxel—ovarian cancer	3.8e-05	0.00105	CcSEcCtD
Melphalan—Connective tissue disorder—Docetaxel—ovarian cancer	3.78e-05	0.00105	CcSEcCtD
Melphalan—Urethral disorder—Docetaxel—ovarian cancer	3.77e-05	0.00104	CcSEcCtD
Melphalan—Hyponatraemia—Epirubicin—ovarian cancer	3.77e-05	0.00104	CcSEcCtD
Melphalan—Renal failure acute—Doxorubicin—ovarian cancer	3.76e-05	0.00104	CcSEcCtD
Melphalan—SLC7A5—Amino acid and oligopeptide SLC transporters—SLC5A5—ovarian cancer	3.76e-05	0.065	CbGpPWpGaD
Melphalan—Nausea—Chlorambucil—ovarian cancer	3.74e-05	0.00103	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	3.66e-05	0.0633	CbGpPWpGaD
Melphalan—Anaemia—Paclitaxel—ovarian cancer	3.65e-05	0.00101	CcSEcCtD
Melphalan—Flushing—Docetaxel—ovarian cancer	3.57e-05	0.000987	CcSEcCtD
Melphalan—Cardiac arrest—Epirubicin—ovarian cancer	3.57e-05	0.000986	CcSEcCtD
Melphalan—Vomiting—Topotecan—ovarian cancer	3.57e-05	0.000985	CcSEcCtD
Melphalan—Leukopenia—Paclitaxel—ovarian cancer	3.54e-05	0.000978	CcSEcCtD
Melphalan—Rash—Topotecan—ovarian cancer	3.54e-05	0.000977	CcSEcCtD
Melphalan—Hypersensitivity—Vinorelbine—ovarian cancer	3.54e-05	0.000977	CcSEcCtD
Melphalan—Dermatitis—Topotecan—ovarian cancer	3.53e-05	0.000976	CcSEcCtD
Melphalan—Hyponatraemia—Doxorubicin—ovarian cancer	3.49e-05	0.000964	CcSEcCtD
Melphalan—Immune system disorder—Docetaxel—ovarian cancer	3.48e-05	0.000961	CcSEcCtD
Melphalan—Mediastinal disorder—Docetaxel—ovarian cancer	3.47e-05	0.000959	CcSEcCtD
Melphalan—Liver function test abnormal—Epirubicin—ovarian cancer	3.47e-05	0.000958	CcSEcCtD
Melphalan—Cough—Paclitaxel—ovarian cancer	3.45e-05	0.000953	CcSEcCtD
Melphalan—Asthenia—Vinorelbine—ovarian cancer	3.44e-05	0.000951	CcSEcCtD
Melphalan—Arrhythmia—Docetaxel—ovarian cancer	3.44e-05	0.00095	CcSEcCtD
Melphalan—Convulsion—Paclitaxel—ovarian cancer	3.43e-05	0.000947	CcSEcCtD
Melphalan—Alopecia—Docetaxel—ovarian cancer	3.4e-05	0.00094	CcSEcCtD
Melphalan—Pruritus—Vinorelbine—ovarian cancer	3.39e-05	0.000938	CcSEcCtD
Melphalan—Myalgia—Paclitaxel—ovarian cancer	3.37e-05	0.00093	CcSEcCtD
Melphalan—Chest pain—Paclitaxel—ovarian cancer	3.37e-05	0.00093	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	3.34e-05	0.000924	CcSEcCtD
Melphalan—Nausea—Topotecan—ovarian cancer	3.33e-05	0.000921	CcSEcCtD
Melphalan—Cardiac arrest—Doxorubicin—ovarian cancer	3.3e-05	0.000913	CcSEcCtD
Melphalan—Diarrhoea—Vinorelbine—ovarian cancer	3.28e-05	0.000907	CcSEcCtD
Melphalan—Anaphylactic shock—Paclitaxel—ovarian cancer	3.23e-05	0.000892	CcSEcCtD
Melphalan—Oedema—Paclitaxel—ovarian cancer	3.23e-05	0.000892	CcSEcCtD
Melphalan—Liver function test abnormal—Doxorubicin—ovarian cancer	3.21e-05	0.000886	CcSEcCtD
Melphalan—Infection—Paclitaxel—ovarian cancer	3.21e-05	0.000886	CcSEcCtD
Melphalan—Thrombocytopenia—Paclitaxel—ovarian cancer	3.16e-05	0.000873	CcSEcCtD
Melphalan—Tachycardia—Paclitaxel—ovarian cancer	3.15e-05	0.00087	CcSEcCtD
Melphalan—Skin disorder—Paclitaxel—ovarian cancer	3.13e-05	0.000866	CcSEcCtD
Melphalan—Anaemia—Docetaxel—ovarian cancer	3.1e-05	0.000856	CcSEcCtD
Melphalan—Pancytopenia—Epirubicin—ovarian cancer	3.08e-05	0.000851	CcSEcCtD
Melphalan—Anorexia—Paclitaxel—ovarian cancer	3.08e-05	0.00085	CcSEcCtD
Melphalan—Vomiting—Vinorelbine—ovarian cancer	3.05e-05	0.000843	CcSEcCtD
Melphalan—Neutropenia—Epirubicin—ovarian cancer	3.03e-05	0.000838	CcSEcCtD
Melphalan—Rash—Vinorelbine—ovarian cancer	3.03e-05	0.000836	CcSEcCtD
Melphalan—Dermatitis—Vinorelbine—ovarian cancer	3.02e-05	0.000835	CcSEcCtD
Melphalan—Hypotension—Paclitaxel—ovarian cancer	3.02e-05	0.000833	CcSEcCtD
Melphalan—Leukopenia—Docetaxel—ovarian cancer	3e-05	0.000829	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	2.94e-05	0.000812	CcSEcCtD
Melphalan—Cough—Docetaxel—ovarian cancer	2.92e-05	0.000808	CcSEcCtD
Melphalan—Convulsion—Docetaxel—ovarian cancer	2.9e-05	0.000802	CcSEcCtD
Melphalan—Paraesthesia—Paclitaxel—ovarian cancer	2.9e-05	0.000801	CcSEcCtD
Melphalan—Dyspnoea—Paclitaxel—ovarian cancer	2.88e-05	0.000795	CcSEcCtD
Melphalan—Myalgia—Docetaxel—ovarian cancer	2.85e-05	0.000788	CcSEcCtD
Melphalan—Chest pain—Docetaxel—ovarian cancer	2.85e-05	0.000788	CcSEcCtD
Melphalan—Pancytopenia—Doxorubicin—ovarian cancer	2.85e-05	0.000788	CcSEcCtD
Melphalan—Nausea—Vinorelbine—ovarian cancer	2.85e-05	0.000787	CcSEcCtD
Melphalan—Dyspepsia—Paclitaxel—ovarian cancer	2.84e-05	0.000785	CcSEcCtD
Melphalan—Neuropathy peripheral—Epirubicin—ovarian cancer	2.84e-05	0.000784	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	2.83e-05	0.000783	CcSEcCtD
Melphalan—Stomatitis—Epirubicin—ovarian cancer	2.82e-05	0.000779	CcSEcCtD
Melphalan—Jaundice—Epirubicin—ovarian cancer	2.82e-05	0.000779	CcSEcCtD
Melphalan—Neutropenia—Doxorubicin—ovarian cancer	2.81e-05	0.000776	CcSEcCtD
Melphalan—Decreased appetite—Paclitaxel—ovarian cancer	2.81e-05	0.000775	CcSEcCtD
Melphalan—Gastrointestinal disorder—Paclitaxel—ovarian cancer	2.79e-05	0.00077	CcSEcCtD
Melphalan—Fatigue—Paclitaxel—ovarian cancer	2.78e-05	0.000769	CcSEcCtD
Melphalan—Pain—Paclitaxel—ovarian cancer	2.76e-05	0.000763	CcSEcCtD
Melphalan—Hepatobiliary disease—Epirubicin—ovarian cancer	2.74e-05	0.000756	CcSEcCtD
Melphalan—Anaphylactic shock—Docetaxel—ovarian cancer	2.74e-05	0.000756	CcSEcCtD
Melphalan—Oedema—Docetaxel—ovarian cancer	2.74e-05	0.000756	CcSEcCtD
Melphalan—Infection—Docetaxel—ovarian cancer	2.72e-05	0.000751	CcSEcCtD
Melphalan—Thrombocytopenia—Docetaxel—ovarian cancer	2.68e-05	0.00074	CcSEcCtD
Melphalan—Ibuprofen—ABCB1—ovarian cancer	2.67e-05	0.199	CrCbGaD
Melphalan—Tachycardia—Docetaxel—ovarian cancer	2.67e-05	0.000738	CcSEcCtD
Melphalan—Skin disorder—Docetaxel—ovarian cancer	2.66e-05	0.000734	CcSEcCtD
Melphalan—Neuropathy peripheral—Doxorubicin—ovarian cancer	2.62e-05	0.000725	CcSEcCtD
Melphalan—Haemoglobin—Epirubicin—ovarian cancer	2.61e-05	0.000721	CcSEcCtD
Melphalan—Stomatitis—Doxorubicin—ovarian cancer	2.61e-05	0.000721	CcSEcCtD
Melphalan—Jaundice—Doxorubicin—ovarian cancer	2.61e-05	0.000721	CcSEcCtD
Melphalan—Anorexia—Docetaxel—ovarian cancer	2.61e-05	0.00072	CcSEcCtD
Melphalan—Haemorrhage—Epirubicin—ovarian cancer	2.6e-05	0.000718	CcSEcCtD
Melphalan—Hepatitis—Epirubicin—ovarian cancer	2.6e-05	0.000718	CcSEcCtD
Melphalan—Urinary tract disorder—Epirubicin—ovarian cancer	2.56e-05	0.000709	CcSEcCtD
Melphalan—Urticaria—Paclitaxel—ovarian cancer	2.56e-05	0.000708	CcSEcCtD
Melphalan—Hypotension—Docetaxel—ovarian cancer	2.56e-05	0.000706	CcSEcCtD
Melphalan—Connective tissue disorder—Epirubicin—ovarian cancer	2.55e-05	0.000705	CcSEcCtD
Melphalan—Urethral disorder—Epirubicin—ovarian cancer	2.55e-05	0.000703	CcSEcCtD
Melphalan—Hepatobiliary disease—Doxorubicin—ovarian cancer	2.53e-05	0.000699	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Docetaxel—ovarian cancer	2.49e-05	0.000689	CcSEcCtD
Melphalan—Paraesthesia—Docetaxel—ovarian cancer	2.46e-05	0.000679	CcSEcCtD
Melphalan—Dyspnoea—Docetaxel—ovarian cancer	2.44e-05	0.000674	CcSEcCtD
Melphalan—Haemoglobin—Doxorubicin—ovarian cancer	2.42e-05	0.000667	CcSEcCtD
Melphalan—Flushing—Epirubicin—ovarian cancer	2.41e-05	0.000666	CcSEcCtD
Melphalan—Dyspepsia—Docetaxel—ovarian cancer	2.41e-05	0.000665	CcSEcCtD
Melphalan—Hepatitis—Doxorubicin—ovarian cancer	2.4e-05	0.000664	CcSEcCtD
Melphalan—Haemorrhage—Doxorubicin—ovarian cancer	2.4e-05	0.000664	CcSEcCtD
Melphalan—Decreased appetite—Docetaxel—ovarian cancer	2.38e-05	0.000657	CcSEcCtD
Melphalan—Hypersensitivity—Paclitaxel—ovarian cancer	2.38e-05	0.000657	CcSEcCtD
Melphalan—Urinary tract disorder—Doxorubicin—ovarian cancer	2.37e-05	0.000656	CcSEcCtD
Melphalan—Gastrointestinal disorder—Docetaxel—ovarian cancer	2.36e-05	0.000653	CcSEcCtD
Melphalan—Connective tissue disorder—Doxorubicin—ovarian cancer	2.36e-05	0.000652	CcSEcCtD
Melphalan—Fatigue—Docetaxel—ovarian cancer	2.36e-05	0.000652	CcSEcCtD
Melphalan—Urethral disorder—Doxorubicin—ovarian cancer	2.36e-05	0.000651	CcSEcCtD
Melphalan—Immune system disorder—Epirubicin—ovarian cancer	2.35e-05	0.000648	CcSEcCtD
Melphalan—Mediastinal disorder—Epirubicin—ovarian cancer	2.34e-05	0.000647	CcSEcCtD
Melphalan—Pain—Docetaxel—ovarian cancer	2.34e-05	0.000646	CcSEcCtD
Melphalan—Arrhythmia—Epirubicin—ovarian cancer	2.32e-05	0.000641	CcSEcCtD
Melphalan—Asthenia—Paclitaxel—ovarian cancer	2.32e-05	0.00064	CcSEcCtD
Melphalan—Alopecia—Epirubicin—ovarian cancer	2.29e-05	0.000634	CcSEcCtD
Melphalan—Pruritus—Paclitaxel—ovarian cancer	2.28e-05	0.000631	CcSEcCtD
Melphalan—Flushing—Doxorubicin—ovarian cancer	2.23e-05	0.000616	CcSEcCtD
Melphalan—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—ovarian cancer	2.21e-05	0.0383	CbGpPWpGaD
Melphalan—Diarrhoea—Paclitaxel—ovarian cancer	2.21e-05	0.00061	CcSEcCtD
Melphalan—Immune system disorder—Doxorubicin—ovarian cancer	2.17e-05	0.0006	CcSEcCtD
Melphalan—Mediastinal disorder—Doxorubicin—ovarian cancer	2.17e-05	0.000598	CcSEcCtD
Melphalan—Arrhythmia—Doxorubicin—ovarian cancer	2.15e-05	0.000593	CcSEcCtD
Melphalan—Alopecia—Doxorubicin—ovarian cancer	2.12e-05	0.000587	CcSEcCtD
Melphalan—Anaemia—Epirubicin—ovarian cancer	2.09e-05	0.000577	CcSEcCtD
Melphalan—Vomiting—Paclitaxel—ovarian cancer	2.05e-05	0.000567	CcSEcCtD
Melphalan—Rash—Paclitaxel—ovarian cancer	2.03e-05	0.000562	CcSEcCtD
Melphalan—Dermatitis—Paclitaxel—ovarian cancer	2.03e-05	0.000562	CcSEcCtD
Melphalan—Leukopenia—Epirubicin—ovarian cancer	2.02e-05	0.000559	CcSEcCtD
Melphalan—Hypersensitivity—Docetaxel—ovarian cancer	2.02e-05	0.000557	CcSEcCtD
Melphalan—Cough—Epirubicin—ovarian cancer	1.97e-05	0.000545	CcSEcCtD
Melphalan—Asthenia—Docetaxel—ovarian cancer	1.96e-05	0.000542	CcSEcCtD
Melphalan—Convulsion—Epirubicin—ovarian cancer	1.96e-05	0.000541	CcSEcCtD
Melphalan—Pruritus—Docetaxel—ovarian cancer	1.94e-05	0.000535	CcSEcCtD
Melphalan—Anaemia—Doxorubicin—ovarian cancer	1.93e-05	0.000534	CcSEcCtD
Melphalan—Myalgia—Epirubicin—ovarian cancer	1.92e-05	0.000532	CcSEcCtD
Melphalan—Chest pain—Epirubicin—ovarian cancer	1.92e-05	0.000532	CcSEcCtD
Melphalan—Nausea—Paclitaxel—ovarian cancer	1.92e-05	0.00053	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	1.91e-05	0.000528	CcSEcCtD
Melphalan—Leukopenia—Doxorubicin—ovarian cancer	1.87e-05	0.000517	CcSEcCtD
Melphalan—Diarrhoea—Docetaxel—ovarian cancer	1.87e-05	0.000517	CcSEcCtD
Melphalan—Anaphylactic shock—Epirubicin—ovarian cancer	1.85e-05	0.00051	CcSEcCtD
Melphalan—Oedema—Epirubicin—ovarian cancer	1.85e-05	0.00051	CcSEcCtD
Melphalan—Infection—Epirubicin—ovarian cancer	1.83e-05	0.000506	CcSEcCtD
Melphalan—Cough—Doxorubicin—ovarian cancer	1.83e-05	0.000504	CcSEcCtD
Melphalan—Convulsion—Doxorubicin—ovarian cancer	1.81e-05	0.000501	CcSEcCtD
Melphalan—Thrombocytopenia—Epirubicin—ovarian cancer	1.81e-05	0.000499	CcSEcCtD
Melphalan—Tachycardia—Epirubicin—ovarian cancer	1.8e-05	0.000498	CcSEcCtD
Melphalan—Skin disorder—Epirubicin—ovarian cancer	1.79e-05	0.000495	CcSEcCtD
Melphalan—Chest pain—Doxorubicin—ovarian cancer	1.78e-05	0.000492	CcSEcCtD
Melphalan—Myalgia—Doxorubicin—ovarian cancer	1.78e-05	0.000492	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	1.77e-05	0.000489	CcSEcCtD
Melphalan—Anorexia—Epirubicin—ovarian cancer	1.76e-05	0.000486	CcSEcCtD
Melphalan—Vomiting—Docetaxel—ovarian cancer	1.74e-05	0.000481	CcSEcCtD
Melphalan—Rash—Docetaxel—ovarian cancer	1.72e-05	0.000477	CcSEcCtD
Melphalan—Hypotension—Epirubicin—ovarian cancer	1.72e-05	0.000476	CcSEcCtD
Melphalan—Dermatitis—Docetaxel—ovarian cancer	1.72e-05	0.000476	CcSEcCtD
Melphalan—Oedema—Doxorubicin—ovarian cancer	1.71e-05	0.000472	CcSEcCtD
Melphalan—Anaphylactic shock—Doxorubicin—ovarian cancer	1.71e-05	0.000472	CcSEcCtD
Melphalan—Infection—Doxorubicin—ovarian cancer	1.7e-05	0.000469	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Epirubicin—ovarian cancer	1.68e-05	0.000464	CcSEcCtD
Melphalan—Thrombocytopenia—Doxorubicin—ovarian cancer	1.67e-05	0.000462	CcSEcCtD
Melphalan—Tachycardia—Doxorubicin—ovarian cancer	1.67e-05	0.00046	CcSEcCtD
Melphalan—Skin disorder—Doxorubicin—ovarian cancer	1.66e-05	0.000458	CcSEcCtD
Melphalan—Paraesthesia—Epirubicin—ovarian cancer	1.66e-05	0.000458	CcSEcCtD
Melphalan—Dyspnoea—Epirubicin—ovarian cancer	1.64e-05	0.000455	CcSEcCtD
Melphalan—Anorexia—Doxorubicin—ovarian cancer	1.63e-05	0.00045	CcSEcCtD
Melphalan—Nausea—Docetaxel—ovarian cancer	1.62e-05	0.000449	CcSEcCtD
Melphalan—Dyspepsia—Epirubicin—ovarian cancer	1.62e-05	0.000449	CcSEcCtD
Melphalan—Decreased appetite—Epirubicin—ovarian cancer	1.6e-05	0.000443	CcSEcCtD
Melphalan—Hypotension—Doxorubicin—ovarian cancer	1.6e-05	0.000441	CcSEcCtD
Melphalan—Gastrointestinal disorder—Epirubicin—ovarian cancer	1.59e-05	0.00044	CcSEcCtD
Melphalan—Fatigue—Epirubicin—ovarian cancer	1.59e-05	0.00044	CcSEcCtD
Melphalan—Pain—Epirubicin—ovarian cancer	1.58e-05	0.000436	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	1.56e-05	0.027	CbGpPWpGaD
Melphalan—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	1.56e-05	0.00043	CcSEcCtD
Melphalan—Paraesthesia—Doxorubicin—ovarian cancer	1.53e-05	0.000424	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	1.53e-05	0.0265	CbGpPWpGaD
Melphalan—Dyspnoea—Doxorubicin—ovarian cancer	1.52e-05	0.000421	CcSEcCtD
Melphalan—Dyspepsia—Doxorubicin—ovarian cancer	1.5e-05	0.000415	CcSEcCtD
Melphalan—Decreased appetite—Doxorubicin—ovarian cancer	1.48e-05	0.00041	CcSEcCtD
Melphalan—Gastrointestinal disorder—Doxorubicin—ovarian cancer	1.47e-05	0.000407	CcSEcCtD
Melphalan—Fatigue—Doxorubicin—ovarian cancer	1.47e-05	0.000407	CcSEcCtD
Melphalan—Urticaria—Epirubicin—ovarian cancer	1.47e-05	0.000405	CcSEcCtD
Melphalan—Pain—Doxorubicin—ovarian cancer	1.46e-05	0.000403	CcSEcCtD
Melphalan—Hypersensitivity—Epirubicin—ovarian cancer	1.36e-05	0.000376	CcSEcCtD
Melphalan—Urticaria—Doxorubicin—ovarian cancer	1.36e-05	0.000375	CcSEcCtD
Melphalan—Asthenia—Epirubicin—ovarian cancer	1.32e-05	0.000366	CcSEcCtD
Melphalan—Pruritus—Epirubicin—ovarian cancer	1.31e-05	0.000361	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—CAV1—ovarian cancer	1.29e-05	0.0224	CbGpPWpGaD
Melphalan—Diarrhoea—Epirubicin—ovarian cancer	1.26e-05	0.000349	CcSEcCtD
Melphalan—Hypersensitivity—Doxorubicin—ovarian cancer	1.26e-05	0.000348	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—RAD51C—ovarian cancer	1.24e-05	0.0214	CbGpPWpGaD
Melphalan—Asthenia—Doxorubicin—ovarian cancer	1.22e-05	0.000338	CcSEcCtD
Melphalan—Pruritus—Doxorubicin—ovarian cancer	1.21e-05	0.000334	CcSEcCtD
Melphalan—Vomiting—Epirubicin—ovarian cancer	1.17e-05	0.000324	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	1.17e-05	0.0202	CbGpPWpGaD
Melphalan—Diarrhoea—Doxorubicin—ovarian cancer	1.17e-05	0.000323	CcSEcCtD
Melphalan—Rash—Epirubicin—ovarian cancer	1.16e-05	0.000321	CcSEcCtD
Melphalan—Dermatitis—Epirubicin—ovarian cancer	1.16e-05	0.000321	CcSEcCtD
Melphalan—Nausea—Epirubicin—ovarian cancer	1.1e-05	0.000303	CcSEcCtD
Melphalan—Vomiting—Doxorubicin—ovarian cancer	1.09e-05	0.0003	CcSEcCtD
Melphalan—Rash—Doxorubicin—ovarian cancer	1.08e-05	0.000297	CcSEcCtD
Melphalan—Dermatitis—Doxorubicin—ovarian cancer	1.08e-05	0.000297	CcSEcCtD
Melphalan—Nausea—Doxorubicin—ovarian cancer	1.01e-05	0.00028	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—AQP3—ovarian cancer	9.94e-06	0.0172	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	9.89e-06	0.0171	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	9.56e-06	0.0165	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ATP7B—ovarian cancer	9.53e-06	0.0165	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CB—ovarian cancer	9.02e-06	0.0156	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—TUBB3—ovarian cancer	7.54e-06	0.013	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—NRAS—ovarian cancer	6.95e-06	0.012	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SPARC—ovarian cancer	6.6e-06	0.0114	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—KRAS—ovarian cancer	5.99e-06	0.0104	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CA—ovarian cancer	5.5e-06	0.00951	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—HRAS—ovarian cancer	5.09e-06	0.0088	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—AQP3—ovarian cancer	5.06e-06	0.00876	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	5.04e-06	0.00872	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.03e-06	0.0087	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	4.87e-06	0.00842	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.86e-06	0.0084	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.86e-06	0.0084	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SOD1—ovarian cancer	4.79e-06	0.00829	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PPP2R1A—ovarian cancer	4.77e-06	0.00825	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NME2—ovarian cancer	3.96e-06	0.00685	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.84e-06	0.00664	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.83e-06	0.00663	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CAV1—ovarian cancer	3.5e-06	0.00606	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CG—ovarian cancer	3.19e-06	0.00552	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CD—ovarian cancer	2.81e-06	0.00485	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.56e-06	0.00443	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYTB—ovarian cancer	2.55e-06	0.00441	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.47e-06	0.00428	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CB—ovarian cancer	2.45e-06	0.00423	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IL2—ovarian cancer	2.25e-06	0.00389	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PPP1CC—ovarian cancer	2.23e-06	0.00386	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—BRIP1—ovarian cancer	2.23e-06	0.00386	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.95e-06	0.00338	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—VEGFA—ovarian cancer	1.91e-06	0.0033	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—NRAS—ovarian cancer	1.89e-06	0.00326	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—MAPK3—ovarian cancer	1.81e-06	0.00312	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—MAPK1—ovarian cancer	1.72e-06	0.00297	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—KRAS—ovarian cancer	1.62e-06	0.00281	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—YAP1—ovarian cancer	1.5e-06	0.00259	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CA—ovarian cancer	1.49e-06	0.00258	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TP53—ovarian cancer	1.44e-06	0.0025	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HRAS—ovarian cancer	1.38e-06	0.00239	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—FASN—ovarian cancer	1.22e-06	0.00211	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—AKT1—ovarian cancer	1.22e-06	0.00211	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC5A5—ovarian cancer	1.2e-06	0.00207	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC2A1—ovarian cancer	1.16e-06	0.002	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP1B1—ovarian cancer	1.11e-06	0.00192	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PPP2R1A—ovarian cancer	9.85e-07	0.0017	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ABCB1—ovarian cancer	9.15e-07	0.00158	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TYMS—ovarian cancer	8.98e-07	0.00155	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CAV1—ovarian cancer	7.24e-07	0.00125	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CG—ovarian cancer	6.59e-07	0.00114	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CD—ovarian cancer	5.8e-07	0.001	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CB—ovarian cancer	5.05e-07	0.000874	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTEN—ovarian cancer	4.37e-07	0.000755	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CA—ovarian cancer	3.08e-07	0.000533	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—AKT1—ovarian cancer	2.52e-07	0.000435	CbGpPWpGaD
